Estrogen and Progestin, Lipoprotein(a), and the Risk of Recurrent Coronary Heart Disease Events After Menopause
Article Abstract:
Women with high lipoprotein(a) [Lp(a)] levels may benefit from estrogen/progestin treatment. Elevated blood levels of Lp(a) are a risk factor for coronary heart disease. In a study of 2,763 postmenopausal women with coronary heart disease, those with elevated Lp(a) levels were more likely to have chest pain or a heart attack. Estrogen and progestin treatment lowered Lp(a) levels compared to treatment with a placebo. This effect was most noticeable in women with very high levels of Lp(a).
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Effect of hysterectomy vs. medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial
Article Abstract:
Hysterectomy is a major surgical procedure carried out for non obstetric reasons more commonly in United States. The effect of hysterectomy is compared with expanded medical treatment on health-related quality of life.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
Article Abstract:
Postmenopausal women who need to take estrogen replacement therapy should also take a progestin to prevent the development of endometrial hyperplasia. Endometrial hyperplasia can be a precursor to endometrial cancer. Researchers followed 596 postmenopausal women who were randomly assigned to take a daily placebo, estrogen alone, or one of three estrogen/progestin combinations. The women had annual endometrial biopsies and were followed for three years. At the end of the study, 85% of the women had normal biopsies. The incidence of endometrial hyperplasia was much higher in the women taking estrogen alone, while the incidence in women taking estrogen/progestin combinations was no higher than the incidence in women taking a placebo. Almost two-thirds of those taking estrogen alone developed hyperplasia. Eighty-six percent of all women with simple hyperplasia reverted to normal spontaneously or following treatment. Women taking estrogen alone accounted for 66% of unscheduled biopsies, 86% of D&Cs and 50% of hysterectomies.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Effect of Estrogen on Brain Activation Patterns in Postmenopausal Women During Working Memory Tasks. Estrogen and Alzheimer Disease Plausible Theory, Negative Clinical Trial
- Abstracts: The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial
- Abstracts: Adherence to postmenopausal hormone therapy during the year after the initial prescription: a population-based study
- Abstracts: Patterns of congenital anomalies and relationship to initial maternal fasting glucose levels in pregnancies complicated by type 2 and gestational diabetes
- Abstracts: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease